KBC Securities - EKOPAK NV (EKOP) Ekopak FRN – feedback analyst call FY23 results

Report

KBC Securities

Kristof Samoy

Ekopak FRN – feedback analyst call FY23 results

Ekopak delivered a good operational performance over FY23 in line with expectations and the outlook drawn for 2024 matches our revenue forecasts. Below are key take-aways from the analyst call with CEO and CFO. Our first read of the press release made to much of the statement on strategy finetuning: the company has no intentions to do acquisitions in the short term.

25/03/2024 1 EN

Underlying

EKOPAK NV

See profile

BE0974380124 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Kristof Samoy

Other Reports on these Companies

KBC Securities

Local Champions Midcap Conference Book 12.12.2024

December 10, 2024 December 10, 2024 1 EN

KBC Securities

Morning Notes : AALB NA, ELI BB, IMMO BB, MELE BB, EKOP BB, MAAT FP

: AALB NA, ELI BB, IMMO BB, MELE BB, EKOP BB, MAAT FP

December 10, 2024 December 10, 2024 1 EN

KBC Securities

Morning Notes : BAR BB, HYL BB, SIP BB, EKOP BB, AUTL US

: BAR BB, HYL BB, SIP BB, EKOP BB, AUTL US

October 17, 2024 October 17, 2024 1 EN

Morning Notes : GIMB BB, SOF BB, MAAT FP

: GIMB BB, SOF BB, MAAT FP

8h / 2m 8h / 2m 1 EN

Jacob Mekhael

Jacob Mekhael

MaaT Pharma FIRST LOOK: DSMB recommends MaaT033 phase 2b continues as planned

MaaT announced that the DSMB (safety board) completed its routine safety assessment of the phase 2b trial (PHOEBUS) of MaaT033 (microbiome therapy, oral capsule) in patients post allo-HSCT, and recommended continuation of the trial without modification. The trial is expected to include the last patient in 2Q26, which means a readout can be expected in 2H27. MaaT033 is next in line after lead product MaaT013 (microbiome therapy, enema formulation), and being an oral capsule means the product could go after the larger commercial opportunity of post-transplant prophylaxis. We reiterate our € 18 T...

8h / 18m 8h / 18m 1 EN

Sharad Kumar S.P

Sharad Kumar S.P

Sofina Newsletter 15: NAVps up 12% y/y aided by recovery across PE & VC

ENAV grew by 12% y/y and came in at €10.1bn or €307ps. We see the NAV growth as further evidence of operational excellence of portfolio companies and rebound in both activity and valuations across PE and VC. NAV growth was mainly driven by Sofina Growth which rose, during 2H FY24, by 15.8% to ~€2.2bn. As expected, EG Software is now one of the top-10 investments in the portfolio. During FY24, Sofina invested in Cyera ($3bn valuation), Finova Capital ($728m valuation) and Vivobarefoot while partially exiting K12 Techno Services, Vinted, Honasa Consumer (Mamaearth) and fully exiting Aohua and TC...

8h / 41m 8h / 41m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Ekopak FRN – feedback analyst call FY23 results

We are a financial services provider for several types of professional clients, each with distinct needs.

Local Champions Midcap Conference Book 12.12.2024

Morning Notes : AALB NA, ELI BB, IMMO BB, MELE BB, EKOP BB, MAAT FP

Morning Notes : BAR BB, HYL BB, SIP BB, EKOP BB, AUTL US

Morning Notes : GIMB BB, SOF BB, MAAT FP

MaaT Pharma FIRST LOOK: DSMB recommends MaaT033 phase 2b continues as planned

Sofina Newsletter 15: NAVps up 12% y/y aided by recovery across PE & VC

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe